Each year, the Journal for ImmunoTherapy of Cancer announces awards for the best papers published in the journal in five different categories. These awards “celebrate excellence in scientific research” and are awarded to “researchers demonstrating leadership in the field as well as innovation and high-quality execution and discussion in their manuscripts”.
A paper led by Dr James McAuliffe from Ludwig Oxford’s Van den Eynde laboratory has won the 2022 award for the best basic tumour immunology paper.
This research demonstrated that the technology behind the Oxford-AstraZeneca COVID-19 vaccine has potential in treating cancer. In pre-clinical models, the team showed that a viral vector cancer vaccine generates effective anti-tumour immune responses and, in combination with immunotherapy, decreases tumour size and increases survival rates. A first-in-human clinical trial of the therapeutic cancer vaccine in patients with non-small cell lung cancer dosed its first patient earlier this year.